Who Paid My Doc
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age
ClinicalTrials.gov NCT06810505
Research payments
$18,460
Through program year 2025, $18,460 in research payments was reported against A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age, across 31 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT06810505
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $18,460 | 31 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rennan Quijano Madisonville, KY Named on 1 payment
- Chad Whyte Omaha, NE Named on 1 payment
- Jennifer McVige Amherst, NY Named on 1 payment
- James Fry Nashville, TN Named on 1 payment
- Niaz Ausaf Sarasota, FL Named on 1 payment
- Joel Saper Ann Arbor, MI Named on 1 payment
- Doris Diaz Miami Lakes, FL Named on 1 payment
- Sherry Soefje Oceanside, CA Named on 1 payment
- Carlos Escasena Coral Gables, FL Named on 1 payment
- Renea Henderson Little Rock, AR Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.